Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges
- PMID: 35673598
- PMCID: PMC9167599
- DOI: 10.2147/JHC.S344559
Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges
Abstract
Obesity has been labeled as the global pandemic of the 21st century, resulting from a sedentary lifestyle and caloric excess. Nonalcoholic fatty liver disease (NAFLD), characterized by excessive hepatic steatosis, is strongly associated with obesity and metabolic syndrome and is estimated to be present in one-quarter of the world population, making it the most common cause of the chronic liver disease (CLD). NAFLD spectrum varies from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. The burden of NAFLD has been predicted to increase in the coming decades resulting in increased rates of decompensated cirrhosis, hepatocellular carcinoma (HCC), and liver-related deaths. In the current review, we describe the pathophysiology of NAFLD and NASH, risk factors associated with disease progression, related complications, and mortality. Later, we have discussed the changing epidemiology of HCC, with NAFLD emerging as the most common cause of CLD and HCC. We have also addressed the risk factors of HCC development in the NAFLD population (including demographic, metabolic, genetic, dietary, and lifestyle factors), presentation of NAFLD-associated HCC, its prognosis, and the issue of HCC development in non-cirrhotic NAFLD. Lastly, the problems related to HCC screening in the NAFLD population, the remaining challenges, and future directions, especially the need to identify the high-risk individuals, will be discussed. We will conclude the review by summarizing the clinical evidence for treating fibrosis and preventing HCC in those at risk with NAFLD-associated HCC.
Keywords: HCC screening; hepatocellular carcinoma; metabolic syndrome; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis.
© 2022 Ahmad et al.
Conflict of interest statement
Dr David Victor is a member of advisory board in Eisai and Exelixis, outside the submitted work. The authors report no other conflicts of interest in this work.
Figures
Similar articles
-
From NASH to HCC: current concepts and future challenges.Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428. doi: 10.1038/s41575-019-0145-7. Nat Rev Gastroenterol Hepatol. 2019. PMID: 31028350 Review.
-
Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.Dig Dis Sci. 2015 Oct;60(10):3142-8. doi: 10.1007/s10620-015-3821-7. Epub 2015 Aug 7. Dig Dis Sci. 2015. PMID: 26250831
-
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. doi: 10.3748/wjg.v23.i47.8263. World J Gastroenterol. 2017. PMID: 29307986 Free PMC article. Review.
-
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103. World J Gastroenterol. 2015. PMID: 25892859 Free PMC article. Review.
-
Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma.World J Hepatol. 2015 Aug 28;7(18):2155-61. doi: 10.4254/wjh.v7.i18.2155. World J Hepatol. 2015. PMID: 26328027 Free PMC article. Review.
Cited by
-
S-Adenosylmethionine: A Multifaceted Regulator in Cancer Pathogenesis and Therapy.Cancers (Basel). 2025 Feb 5;17(3):535. doi: 10.3390/cancers17030535. Cancers (Basel). 2025. PMID: 39941901 Free PMC article. Review.
-
Acetaminophen-Induced Hepatotoxicity in Obesity and Nonalcoholic Fatty Liver Disease: A Critical Review.Livers. 2023 Mar;3(1):33-53. doi: 10.3390/livers3010003. Epub 2023 Jan 12. Livers. 2023. PMID: 36713231 Free PMC article.
-
Obesity and Risk of Liver and Biliary Tract Cancer: Does Timing and Trajectory Matter?JNCI Cancer Spectr. 2022 Aug 9;6(4):pkac057. doi: 10.1093/jncics/pkac057. Online ahead of print. JNCI Cancer Spectr. 2022. PMID: 35944215 Free PMC article. No abstract available.
-
Structural Characterization and Anti-Nonalcoholic Fatty Liver Effect of High-Sulfated Ulva pertusa Polysaccharide.Pharmaceuticals (Basel). 2022 Dec 31;16(1):62. doi: 10.3390/ph16010062. Pharmaceuticals (Basel). 2022. PMID: 36678559 Free PMC article.
-
SIRT2 Deficiency Aggravates Diet-Induced Nonalcoholic Fatty Liver Disease through Modulating Gut Microbiota and Metabolites.Int J Mol Sci. 2023 May 18;24(10):8970. doi: 10.3390/ijms24108970. Int J Mol Sci. 2023. PMID: 37240315 Free PMC article.
References
-
- Obesity and overweight. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed March 20, 2020.
-
- Kivimäki M, Kuosma E, Ferrie JE, et al. Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe. Lancet Public Health. 2017;2(6):e277–e285. doi: 10.1016/S2468-2667(17)30074-9 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources